Findings
Lack of publicly available qualified MDDTs may limit their widespread adoption.
Challenges in collecting robust evidence for novel or innovative tools without established paradigms.
Regulatory complexities for tools with dual uses as MDDTs and clinical diagnostic devices.
The need for transparent communication of MDDT advantages and limitations for their qualified COU.
Limited industry awareness of the benefits and processes for MDDT qualification.

Recommendations
Develop clear and specific Context of Use (COU) statements for proposed MDDTs, detailing their application in device evaluation.
Ensure thorough validation of tool performance characteristics, including accuracy, reproducibility, and reliability, to support qualification.
Foster collaboration among stakeholders, such as consortia and organizations, to share resources for MDDT development and qualification.
Provide detailed qualification plans outlining data collection methods, protocols, and acceptance criteria for each performance metric.
Promote transparency by publishing high-level summaries of evidence and qualification decisions while protecting proprietary information.

Regulatory Considerations
MDDTs intended only for device evaluation are typically not classified as medical devices unless used for clinical treatment or diagnosis.
Clinical study tools used as MDDTs must comply with Investigational Device Exemption (IDE) regulations under 21 CFR Part 812.
Qualification does not imply FDA clearance or approval for clinical use; labeling and promotional materials must clearly communicate this distinction.
Modifications to an MDDT’s COU or qualification status may require reevaluation based on new data or scientific advancements.
FDA emphasizes the complementary role of MDDTs alongside consensus standards and device-specific guidance for regulatory evaluations.